Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
Recruiting · Phase 2 · NCT05766839
Conditions: Hyperkalemia
At a glance
- Research payments reported, 2025
- $116,680
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 36
About the trial
- Sponsor
- Vifor Pharma, Inc.
- Tested
- Patiromer (drug)
- Dates
- Started 2025-04-06; completion 2030-12-01
- Results posted
- Not yet
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Vifor Pharma, Inc. reported $116,680 in research payments for this study in 2025 (22 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mohammad Ilyas, M.D. Pediatric Nephrology · Orlando, FL
- Jeffery A. Johnson, MD Pediatric Nephrology · Orlando, FL
- Chryso P. Katsoufis, M.D. Pediatric Nephrology · Miami, FL
- Vimal Master Sankar Raj, MD Pediatric Nephrology · Peoria, IL
- Bradley A. Warady, MD Pediatric Nephrology · Kansas City, MO
- Rasheed Gbadegesin, M.D. Pediatrics · Durham, NC
- Benjamin L. Laskin, M.D. Pediatric Nephrology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Children's Hospital of Philadelphia, PA $40,424
- Duke University $27,550
- Osf Heart of Mary Medical Center, IL $19,016
- Orlando Health, FL $17,500
- The Children's Mercy Hospital, MO $5,600
- University of Florida $4,550
- University of Miami Dba Umsponsored Programs $2,040
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.